We have assembled a leading team of advisors with deep domain expertise.
Manuel Hidalgo, M.D., Ph.D., a leading physician-scientist specializing in pancreatic cancer and drug development, is the Chief of the Division of Hematology and Medical Oncology and E. Hugh Luckey Distinguished Professor of Medicine at Weill Cornell Medicine/New York-Presbyterian Hospital. Dr Hidalgo is also Associate Director for Clinical Services at the Sandra and Edward Meyer Cancer Center. His research has included development of several anti-cancer drugs including erlotinib, nab-paclitaxel and temsirolimus. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and Ph.D. from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital “12 de Octubre” in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo become the Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, Johns Hopkins University, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. During his time at Beth Israel, Dr. Hidalgo served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School.
Dr. Huang is a professor at the Institute of Systems Biology (ISB), a Seattle-based biomedical research organization that leads the transformation of medicine enabled by genomics and big data. An overarching theme of the Huang Lab at ISB is the interface between normal cell development and cancer development, analyzed through the formal concepts of gene networks and cell population dynamics. In 2019, Dr. Huang was announced as a member of a global research team funded with a $25 million grant from Cancer Research UK. As part of this research, the Huang Lab is in charge of large-scale RNAseq analysis at single-cell resolution that systematically profiles patient tumors to better understand how chronic inflammation causes cancer and to find novel ways of treating cancers by modulating the inflammatory tumor tissue.
Dr. Huang obtained his doctorates in medicine and molecular biology at the University of Zurich in 1995. After completing postdoctoral training in cancer biology, he joined the faculty at Harvard Medical School in Boston and subsequently moved to the University of Calgary to work alongside Stuart Kauffman on gene regulatory networks and cancer differentiation. He joined ISB in 2011, where his laboratory combines single-cell omics technologies and theory of non-linear dynamical systems to dissect and control the fundamental tendency of tumor to progress.
Dr. Patricia LoRusso has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for 30 years, spending the first 25 years at Wayne State University/Karmanos Cancer Institute in Detroit, MI and transitioning to Yale University/Yale Cancer Center in 2014. Both institutions have NCI comprehensive designation status. She has had continuous NIH/NCI peer review funding for 28 years, having held a U-grant for early phase clinical trials through the NCI Cancer Therapy Evaluation Program (CTEP) for 26 years. She has also collaborated on numerous other grants and have been an investigator in P01 and P30 funding mechanisms. Understanding the need for team science, she has participated in P50 mechanisms and has been awarded team science grants through such organizations as Stand Up to Cancer (Co-Leader: Melanoma Dream Team), the Department of Defense (DOD) and the Komen Foundation (Co-leader, KG111063:Targeting Stem Cells in Triple-Negative Breast Cancer (TNBC) in Different Racial Populations).
Dr. LoRusso has also been involved in many service disciplines at the NCI. She has reviewed grants for many study sections and has either been an ad hoc (e.g. CCSG, NeXT study sections) or permanent study section member (e.g. Program Project Subcommittee D and Clinical Oncology study sections). She has served on the Investigational Drug Steering Committee (IDSC) since inception (2005-present) and served as its chair from 2011-2013. She was a member of the steering committee that convened after the Blue-Ribbon Panel to execute on their recommendations. She served a 4-year term (2015-2019) on the Board of Scientific Council (BSC), reviewing the intramural programs for quality, content, productivity and funding.
In addition to serving in NCI positions, Dr. LoRusso has served in leadership positions of several other organizations. She has served on the Board of Directors and numerous scientific and education committees of the American Association for Cancer Research (AACR), the education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop, as examples. Internationally, she has taught several clinical trials educational workshops, educating many physicians and scientists across the globe. She understands how critically important it is to train the next generation of early career investigators to be knowledgeable and proficient in clinical and translational research by providing them leadership opportunities and mentoring. She has worked closely with Cancer Research United Kingdom (CRUK), a UK Welcome Trust which is the second largest funding agency for cancer research. She is currently serving a 3-year term as the chair of their New Agents Committee (NAC), reviewing international proposals relative to drug development of novel agents.
Working closely over the past 3 decades with patients suffering from advanced malignancies, Dr. LoRusso has become an advocate, not only for cancer researchers and clinicians, but more importantly for the patients and their caregivers. Having experienced at a young age the death of her own parents from cancer, she understands the urgent need for new cancer discoveries and the potential for longevity and quality of life.
Dr. Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College.
Dr. O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland. She completed her residency training in Ireland and Fellowship training at MSK. Dr. O’Reilly has pancreatic and hepatobiliary malignancies as the major focus of her research and clinical activities. Research directions include integration of molecular and genetic-based therapies for the treatment of pancreas cancer along with development of adjuvant and neoadjuvant therapies and identification of biomarkers for therapy selection. Dr. O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. Dr.
O’Reilly is the Principal Investigator of multiple trials in pancreas cancer and has authored/co-authored > 300 articles, editorials and book chapters.
Dr. O’Reilly’s other MSK responsibilities include: Chair of the Human Subjects Research Program (HRPP), Chair of the Institutional Review & Privacy Board (IRB) and Chair of the Continuing Medical Education (CME) committee.
Nationally Dr. O’Reilly is Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves on the NCI Gastrointestinal Cancers Steering Committee (GISC), Medical and Scientific Advisory Board of Pancreatic Cancer Action Network, American Society of Clinical Oncology (ASCO) Guidelines Committee and the Board of the National Pancreas Foundation.
Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a Director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, Inc., a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy. Until October 2007 he was SVP, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as VP, Oncology Development, at Amgen and VP, Global Clinical Oncology Development, at Novartis. In those roles he oversaw the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP).
He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, a past member of the FDA Science Board, and is a recipient of the FDA’s Cody Medal. He is a past editor of the Journal of Immunotherapy and past president of the Society of Biological Therapy. He has served on the National Cancer Policy Forum of the Institute of Medicine and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. A past Board Director of the Ontario Institute for Cancer Research, he currently serves as a Board Director for the Multiple Myeloma Research Foundation. He served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for 15 years and is a previous elected Board Director of AACR. Dr. Parkinson was a Director of Facet Biotech, Inc., until the acquisition by Abbott Pharmaceuticals, and was a Director of Ambit Biosciences until the acquisition by Daiichi Sankyo. He was also previously a Director at Threshold Pharmaceuticals and Cerulean Pharmaceuticals. He currently serves as Director on the Boards of CTI Biopharma, Inc (CTIC), 3SBio Inc (1530.HK) and is a Co-Founder and Director of Refuge Biotech, Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.
Dr. Takimoto is the Chief Medical Officer of IGM Biosciences. Dr. Takimoto has 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences. Prior to Gilead, Dr. Takimoto was Chief Medical Officer of Forty Seven, a biotechnology company formed out of Stanford University and acquired by Gilead Sciences in 2020. Dr. Takimoto has also served as Vice President of Experimental Medicine Early Development, Oncology Therapeutic Area for Janssen Research and Development. Prior to Janssen, Dr. Takimoto was Senior Director of Translational Medicine of Ortho Biotech Oncology Research and Development. He has over thirty years of experience in industry and academia, including academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute, and the Uniformed Services University of the Health Sciences. He has also served as a Commissioned Officer in the U.S. Public Health Service. Dr. Takimoto received a B.S. in Chemistry from Stanford University, a Ph.D. in Pharmacology from Yale University, and an M.D. from Yale University School of Medicine.
Inflammatory Bowel Disease
Dr. Hanauer is an internationally recognized expert on the treatment of inflammatory bowel disease. He currently serves as the medical director of the Digestive Disease Center at Northwestern University Feinberg School of Medicine and as the Clifford Joseph Barborka Professor of Medicine. After earning his medical degree from the University of Illinois, Dr. Hanauer completed his internship and residency in internal medicine followed by a fellowship in gastroenterology at the University of Chicago. There Dr. Hanauer was mentored by one of the great clinicians in American gastroenterology, the legendary Dr. Joseph B. Kirsner. Dr. Hanauer held a Professorship in Medicine at Chicago named for Dr. Kirsner.
As Chairman of the Gastrointestinal Drugs Advisory Committee at the US Food and Drug Administration, Dr. Hanauer authored the FDA’s “Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease”. From 2014-2015, he served as president of the American College of Gastroenterology (ACG), where he has been a member of the ACG Board of Trustees since 2006, an officer of the ACG since 2010 and a contributing committee member since 1989. He has represented the ACG at the FDA related to development of end-points for IBD in a series of “GREAT” meetings. He edited Nature Reviews Gastroenterology & Hepatology and chaired the ACG Finance Committee from 2011 to 2012. Dr. Hanauer has also held leadership positions in the American Gastroenterological Association (AGA) as chair of the Sections on Infection, Immunology and Inflammatory Bowel Disease as well as Clinical Practice, and served on the AGA Governing Board as a Counselor for Clinical Research. Internationally, he is a member of the European Crohn’s and Colitis Organization (ECCO) and is a former chairman of the International Organization for IBD (IOIBD).
Dr. Hanauer was awarded the AGA Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology in 2001 and the AGA Janssen Award for Clinical Excellence in GI in 2004. He is currently an Associate Editor for Clinical Gastroenterology and Hepatology. In addition, Dr. Hanauer has worked with the American Board of Internal Medicine serving on the Gastroenterology sub-specialty. He has also held leadership positions within the Crohn’s & Colitis Foundation of American and in 2011 received CCFA’s Scientific Achievement Award for Clinical Research. Over the course of his career, Hanauer has authored or co-authored hundreds of peer-reviewed journal articles, books, book chapters, monographs, and editorials.
Dr. Hyams is one of the world’s leading experts in pediatric inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis. As Head of the Division of Digestive Diseases, Hepatology, and Nutrition at Connecticut Children’s Medical Center, he has led pivotal clinical trials for therapeutic agents in IBD and directed a long-term natural history registry that has described the course of almost 2000 children newly diagnosed with IBD. Dr. Hyams is the recent recipient of a $10.4M grant from the National Institutes of Health investigating the response of children newly diagnosed with ulcerative colitis to standardized therapies. He has worked with the FDA developing endpoints for pediatric clinical trials, has published more than 250 peer reviewed articles, and is the co-editor of one of the standard pediatric digestive disease textbooks, Pediatric Gastrointestinal and Liver Disease. Dr. Hyams was the first pediatrician to ever receive the prestigious Scientific Achievement in IBD Clinical Research Award from the Crohn’s & Colitis Foundation of America. He graduated from University of Pennsylvania School of Medicine and conducted his residency and fellowship at Boston Children’s Hospital.
Dr. Joshua R. Korzenik, one of the leading IBD researchers and key opinion leaders in the country, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and assistant professor at Harvard Medical School. Dr. Korzenik has been involved in IBD research and care of patients for almost 25 years, with his research focusing on 1) translational research in IBD and 2) investigating environmental influences in IBD, with a focus on their common nexus of the intestinal microbiome. Dr. Korzenik is the author of almost 60 peer-reviewed articles and research papers. He speaks frequently at professional meetings and is an active member of many professional committees. Dr. Korzenik has been the principal investigator of over a dozen research projects, ranging from studies of diet and probiotics to international comparisons of IBD. Dr. Korzenik earned his bachelor’s degree from Harvard College in 1980 and his medical degree from Albert Einstein College of Medicine in the Bronx, New York, in 1987. He was a resident at Harvard-affiliated Beth Israel Deaconess Hospital in Boston from 1987 to 1990 and fellow in gastroenterology and clinical epidemiology at Yale University School of Medicine Hospital from 1991 to 1994. He is a longstanding member of the medical advisory committee for the New England chapter of Crohn’s and Colitis Foundation of America.
Dr. Asma Nusrat is a leading research clinician in the field of epithelial wound healing in the context of inflammatory bowel disease (IBD). Asma trained and became certified in Anatomic Pathology at the Brigham and Women’s Hospital (BWH)/Harvard Medical School after which she completed a fellowship in Gastrointestinal and Hepatobiliary pathology, as well as a postdoctoral research fellowship in epithelial cell biology at the same institution. While at BWH, she began investigating fundamental mechanisms of epithelial barrier regulation and wound repair. During this time, she was successful in obtaining NIH funding, advancing from NRSA to K08 grants and rose to the rank of Assistant Professor. She left BWH to join the faculty at Emory University to continue developing a highly successful research program centered on mucosal pathobiology in the gut, training fellows and graduate students and performing clinical service as a gastrointestinal pathologist. At Emory, Asma was highly successful in obtaining multiple NIH grants while remaining clinically active in gastrointestinal surgical pathology. She rapidly rose through the ranks and was promoted to professor with tenure in 2007. In 2015, Asma left Emory to join the faculty in the department of pathology at the University of Michigan where she was appointed as the Aldred Scott Warthin Professor and Director of Experimental Pathology.
In her lab, Asma continues a long standing quest to elucidate the pathologic mechanisms of chronic inflammatory diseases of the gut and mucosal wound repair. She has published more than 150 papers, many in high profile journals, regularly speaks at national and international symposia related to her field, and has served as an Associate Editor for leading journals in the field for over a decade. In addition to her robust research program, Asma remains clinically active as a practicing Gastrointestinal and Liver Pathologist while enjoying mentoring and teaching graduate and medical students, residents, postdoctoral fellows and junior faculty.
Dr. Rieder is an investigator at the Department of Pathobiology and an Associate Staff at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with inflammatory bowel diseases (IBD) with a special emphasis on the field of pathogenesis, prediction and therapy of IBD.
Dr. Rieder has published more than 60 articles and book chapters and has been recognized for his expertise and he serves on multiple committees, speakers’ panels, steering committees and editorial boards. He is a member of the European Crohn’s and Colitis Organization (ECCO), the German Gastroenterology Association, the American Gastroenterology Association, the America Physiological Society, the American College of Physicians, and the Crohn’s and Colitis Foundation. He is the associate editor of Clinical and Translational Gastroenterology, section editor of Annals of Gastroenterology, on the editorial boards of the Journal of Crohn’s and Colitis, Inflammatory Bowel Diseases, BMC Gastroenterology, American Journal of Physiology: Gastrointestinal and Liver Physiology and Gastroenterology and Hepatology Journal. Dr. Rieder is the senior author of the new ECCO guidelines for Ulcerative colitis, the first author of the ECCO consensus on Fibrostenosing IBD and co-author of the new ECCO guidelines in Crohn’s disease.
He received his medical degree from the Ludwig-Maximilians-University Medical School in Germany. He underwent training in Internal Medicine / Gastroenterology at the Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, Germany and a residency in Internal Medicine and fellowship in Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic in Cleveland, Ohio. Dr. Rieder has performed research fellowships at Harvard Medical School and the Cleveland Clinic.
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn’s disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn’s disease.
Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.,
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn’s Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn’s and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for “Excellence in Action” in recognition of his distinguished patient care.
His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut. Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine. Dr. Sands served as an Associate Editor for the field’s leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicinein Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Dr. Colgan is the Director of the Mucosal Inflammation Program and Vice Chairman of the Department of Medicine at the University of Colorado. Dr. Colgan’s research focuses on the identification of novel anti-inflammatory molecules associated with mucosal inflammation. He is one of world’s leading experts on Specialized Proresolving Mediators (SPMs), having served on the faculty at Harvard Medical School in the Center for Experimental Therapeutics under the tutelage of Dr. Charles Serhan, who created the modern field of resolution biology. Dr. Colgan has published more than 170 original papers, served as a Section Editor for the Journal of Immunology, and is a standing member of the GMPB study section at the NIH. He is the previous chairman of the Research Fellowship Award study section for the CCFA and presently serves as the chairman of the CCFA Senior Research Award study section.
Dr. Bruce Levy is a leading expert on Resolvin pharmacology in pulmonary diseases, and his seminal research on Resolvin E1 in ARDS and asthma models laid the foundation for Thetis’ TP-317 program. Dr. Levy is the Division Chief of the Pulmonary and Critical Care Medicine Division at Brigham and Women’s Hospital (BWH) and on faculty at Harvard Medical School. The Bruce Levy Air Inflammation and Resolution Lab focuses on endogenous mechanisms for resolution of lung inflammation and injury. The lab seeks to identify novel pathways and cellular targets that promote resolution of pulmonary inflammation or injury and to determine roles for naturally-derived, specialized pro-resolving mediators in lung health and disease. Dr. Levy is board-certified in critical care medicine and pulmonary disease. He has written more than 120 peer-reviewed publications, and currently serves as associate editor of the American Journal of Respiratory and Critical Care Medicine and The New England Journal of Medicine’s clinical problem-solving interactive case series. Dr. Levy received his medical degree from the University of Pennsylvania School of Medicine (now the Perelman School of Medicine) and completed a fellowship in pulmonary and critical care medicine at BWH.
Charles Nicholas Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and also Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine; He is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Dr. Serhan’s pioneering studies on the chemistry-medicine interface have resulted in the discovery of the Specialized Pro-resolving Mediators (SPMs), a super-family of biochemical mediators that actively orchestrate the resolution of inflammation and provide the molecular underpinnings for a new era in inflammation resolution pharmacology.
Charles received a BS in biochemistry from Stony Brook University followed by a Doctorate in experimental pathology and medical sciences from New York University School of Medicine. He was a visiting scientist and post-doctoral fellow at the Karolinska Institutet, Stockholm with Professor Bengt Samuelsson (Nobel Laurate Medicine 82). In 1987, he joined the faculty at Harvard Medical School and received an honorary degree from Harvard University (1996).
He has received several awards including an NIH MERIT award and has delivered > 50 keynote and plenary lectures. Among these recent awards are: the 2008 William Harvey Outstanding Scientist Medal and AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology Bonazinga Award, The American College of Rheumatology Hench (Nobel Laurate) Award Lecture in 2011 presented by the Mayo Clinic Hench Society, and Mérieux 2013 Laureate.
In 2016, he received the IUBMB Lecture Metal and the Ross Prize in Molecular Medicine. Recently, he received the International Eicosanoid Research Foundation’s 2017 Lifetime Achievement Award and the American Society of Investigative Pathology 2018 Rous Whipple Award and the 2018 Gaddum International Prize and Award Lecture from the British Pharmacology Society.